Retatrutide and tirzepatide are different molecules. Retatrutide is designed around GIP, GLP-1 and glucagon receptor activity, while tirzepatide targets GIP and GLP-1 receptors; one should not be treated as a higher-strength version of the other.
What procurement and laboratory teams should review
Confirm the exact analyte and reference identifier on every file
Compare sequence, molecular mass and conjugation rather than abbreviations
Keep dose, concentration and molar comparisons separate
Do not compare outcomes across unmatched trial designs
Define the molecular form before comparing offers
Sequence alone may not fully define a peptide material. Termini, modifications, disulfide pattern, counterion, hydration state and presentation can affect molecular-weight calculations, analytical reporting, solubility and handling.
- Record sequence, termini and every modification explicitly.
- State the requested salt or counterion form.
- Treat solubility and stability as material- and condition-specific.
Questions to resolve before quotation or release
- Does the COA identify retatrutide or tirzepatide unambiguously?
- Which identity method supports the stated molecule?
- Are comparison materials handled under the same analytical conditions?
Comparative supply should use separate lot-controlled materials and applicable analytical files.
Source material and further reading
This guide is informed by the following primary guidance and established technical resources. Always confirm the current version and its applicability to your material and jurisdiction.
HK PEPTIDES materials are supplied for laboratory research and documentation workflows only. They are not intended for human consumption, diagnostic use, therapeutic use, veterinary use or clinical application.